Young Lag Cho

Chief Development Officer

South Korea

Research Interests

Explore related searches

Professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Young Lag Cho serves as the Chief Development Officer at LegoChem Biosciences Inc in South Korea. His research primarily focuses on the fields of antibacterial agents and tuberculosis treatment, evidenced by his recent articles on the pharmacokinetics of delpazolid and the development of novel antibiotic compounds. He has contributed significantly to clinical trials and in vitro studies aimed at combating resistant bacterial strains.

Articles (6)

Year:

2025

Year:

2024

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

HEE-SOO PARK

Assistant Professor

Kyungpook National University

SOUTH KOREA

View details

Derrick Fouts

Professor

UNITED STATES

View details

Jin-Hwan Kwak

Senshu University

SOUTH KOREA

View details

Jung-Hyun Byun

Assistant professor

Seoul National University Hospital

SOUTH KOREA

View details

Dongeun Yong

Yonsei University College of Medicine

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Young Lag Cho

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

Pharmacokinetic and Pharmacodynamic Modeling Analysis of Delpazolid (LCB01-0371) in Adult Patients with Pulmonary Tuberculosis

Antibacterial Activity of LCB10-0200 against Klebsiella pneumoniae

In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i>, and <i>Pseudomonas aeruginosa</i> Strains at a Tertiary Hospital in Korea

In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. Panel Strains.

Development of delpazolid for the treatment of tuberculosis

Collaborators (5)

HEE-SOO PARK

Derrick Fouts

Jin-Hwan Kwak

Jung-Hyun Byun

Dongeun Yong

Make your next move.